身处乐城，截至今年9月底，瑞金海南医院已成功落地特许药械项目186项，特医食品2项，生物医 学新技术5项，惠及患者超2.68万人次。让我印象深刻的是，伏索利肽作为治疗软骨发育不全的全球独 家新药，在欧盟上市后不到一年时间，便在我们医院完成了全国首例治疗。 如果说乐城"特许药械"解决了"用得上"的问题，那么真实世界研究则加速了"用得好、用得广"的进 程。我们通过开展高质量的临床真实世界数据研究，为国际创新药械在中国的注册上市创造了令业界瞩 目的"乐城速度"。 身处全国唯一的"医疗特区"，我们将充分发挥公立医院的平台优势，赋能区域医疗生态，助推海南 自贸港医疗健康产业高质量发展，加快实现"立足海南、服务全国、辐射东南亚"的国家区域医疗中心建 设目标。(整理/王子豪) ...

Core Viewpoint - Ruijin Hainan Hospital is leveraging institutional innovation to establish itself as a new highland for international medical services in the Hainan Free Trade Port, aiming to connect global medical resources with local patients [3][4][5]. Group 1: Institutional Innovation and Medical Services - Ruijin Hainan Hospital is a key project approved by the Hainan provincial government, officially starting operations in December 2021 and achieving full medical process integration by March 2022 [3][4]. - The hospital has successfully implemented 186 special drug and medical device projects, benefiting over 26,800 patients, significantly reducing the economic burden on patients by negotiating lower prices for these products [5][6]. Group 2: Real-World Research and Clinical Advancements - The hospital is conducting high-quality real-world data research to accelerate the registration and market entry of international innovative drugs and devices in China, exemplified by the rapid approval of Isatuximab injection for multiple myeloma patients [6][7]. - Innovative mechanisms have been established, including a dedicated technical expansion department and a patient management platform, to enhance the accessibility of quality medical resources [6][9]. Group 3: Talent Development and Cultural Integration - The hospital is focusing on a "transfer and cultivate" approach to talent development, aiming to instill the spirit of Ruijin Hospital in Hainan while building a sustainable local talent pool [7][8]. - Collaborative initiatives with Shanghai Jiao Tong University and other institutions are being pursued to provide local talents with international learning and research opportunities [8]. Group 4: Regional Medical Ecosystem and Internationalization - Ruijin Hainan Hospital is enhancing the regional medical ecosystem through platform sharing and resource integration, collaborating with local hospitals to provide high-quality medical services [9]. - The hospital is actively pursuing international cooperation, including partnerships with Southeast Asian medical institutions and exploring international insurance models to improve service standards [9].

Core Insights - The construction of Beijing's "Two Zones" (National Service Industry Expansion Pilot Zone and Free Trade Pilot Zone) has shown significant progress over the past five years, enhancing the city's capacity to attract foreign investment and support enterprises going global [1] Legal Environment Optimization - Beijing has approved the establishment of the Beijing International Law and Business Integration Demonstration Zone, covering 7.04 square kilometers in the CBD, focusing on international business cooperation and overseas service environments [2] - The region hosts over 30% of the city's legal service institutions and has established an international commercial arbitration center, enhancing legal support for businesses [2] - The initiative aims to attract global high-end resources and provide high-quality, international legal and business services to foster economic development in the capital [2] Data Facilitation - The Beijing CBD Service Station has launched a "online + offline" dual service model to assist companies with data compliance and cross-border data flow [3] - Since its operation began in 2024, the service station has supported over 50 companies across various sectors, including pharmaceuticals and banking, in meeting their cross-border data service needs [3] - Future plans include hosting specialized sessions on data security and compliance to further enhance companies' capabilities in data export [3] Rare Disease Medication Accessibility - Beijing has initiated the country's first pilot zone for rare disease medication assurance, exploring clinical application models for imported drugs not registered in China [4] - From April 2024 to July 2025, the Beijing Children's Hospital has successfully applied for temporary imports of a rare disease medication, with a total of 4,460 units approved within an average of 40 days [4] - This efficient approval process has transformed the previous situation of patients waiting for medication, ensuring continuous access to necessary drugs for rare disease patients [4] Global Innovation Drug Market - The pilot zone model in Beijing has demonstrated the convenience of the entire process from diagnosis to medication for rare disease patients, attracting attention from foreign enterprises [5] - The model has highlighted the potential of the Chinese market for global innovative drugs, providing a replicable experience for the registration and use of these drugs in China [5] - The successful promotion of this model is expected to accelerate the entry of global innovative drugs into the Chinese market [5]